ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

MYX Mycelx Technologies Corporation

56.00
4.00 (7.69%)
Last Updated: 13:27:49
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Mycelx Technologies Corporation LSE:MYX London Ordinary Share COM SHS USD0.025 (DI)
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  4.00 7.69% 56.00 53.00 59.00 56.00 52.00 52.50 73,759 13:27:49
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Water Supply 10.03M -3.99M -0.1736 -3.23 12.87M

MyCelx Technologies Corporation Grant of Share Options to Chief Financial Officer

18/03/2024 7:00am

RNS Regulatory News


RNS Number : 1413H
MyCelx Technologies Corporation
18 March 2024
 

18 March 2024

MYCELX Technologies Corporation

("MYCELX" or the "Company") (AIM: MYX)

 

 

Grant of Share Options to Chief Financial Officer

 

On 15 March 2024 Ms. Slayton, a PDMR of the Company, was awarded the following options over the Company's common shares of US$0.025 each ("Common Shares") under the MYCELX Omnibus Performance Incentive Plan ("Plan"):

 

Name of PDMR

Number of share options granted

Exercise price

Total number of share options held following this notification

Total number of share options as % of current issued share capital






Kimberly Slayton

50,000

US$0.59

313,334

1.36%

 

Ms. Slayton holds no Common Shares in the issued capital of the Company.

 

The share options granted to Kimberly Slayton on 15 March 2024 will vest as to 50% on 31 December 2024 and 50% on 31 December 2025. The exercise price was based on the mid-market closing price of the Company's Common Shares at 15 March 2024, and the closing US/£ exchange rate at that date.

 

The above grant is included as part of wider grants of 300,000 options in aggregate to employees across the Company on 13 March 2024 and 15 March 2024, representing 1.31% of the current issued share capital. All of the options must be exercised prior to the tenth anniversary of the date of grant, subject to the restrictions on dealing under the Company's share dealing code.

 

Details of the transaction are reported in the PDMR notification below:

 

1

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

 Kimberly Slayton

2

Reason for the notification

 

a)

Position/status

Chief Financial Officer

 

b)

Initial notification/Amendment

Initial Notification

 

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

MYCELX Technologies Corporation

 

b)

LEI

213800UJZINIK2VD1G48 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

Description of the financial instrument, type of instrument

Grant of options over 50,000 common shares of US$0.025 each.

 

ISIN: US62847T2024

 

c)

Currency

US$

d)

Price(s) and volumes(s)

Price(s)

Volume(s)

 



US$0.59

50,000

e)

Aggregated information

-      Aggregated volume

-      Price

 

As above

f)

Date of the transaction

15 March 2024  

g)

Place of the transaction

NA (grant of options)

 

 

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Ana Ercegovic

 

 

Tel: +44 20 7523 8000

Celicourt Communications (Financial PR)

Mark Antelme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKZGMFKNLGDZM

1 Year Mycelx Technologies Chart

1 Year Mycelx Technologies Chart

1 Month Mycelx Technologies Chart

1 Month Mycelx Technologies Chart

Your Recent History

Delayed Upgrade Clock